Invitae Multi-Cancer Panel

Genetic cancer screening can help you uncover a women’s hereditary health risk before you find a lump. 1 in 4 women in the general population meet criteria for hereditary cancer genetic testing.

Family history alone isn’t enough to determine a woman’s risk of cancer. Comprehensive risk assessment and genetic testing for all women helps you identify those who may need additional health care.

Nearly half of patients with a BRCA1 or BRCA2 genetic variant do not have a suggestive family history—but need additional care knowing their genetic status before a breast cancer diagnosis leads to improved survival rates. For those patients who test negative for pathogenic variants, Invitae can provide a Tyrer-Cuzick score, so you can get a more complete picture. The 5-year survival rate in patients who knew heir BRCA1/BRCA2 status before diagnosis is 94% compared with 78% in patients who only found out their status after diagnosis (P<0.03).

The Invitae Multi-Cancer Panel analyzes genes that are associated with hereditary predisposition to adult-onset cancers across major organ systems including, but not limited to, breast, gynecologic, endocrine, skin, and brain/nervous system. Adult-onset hereditary cancers are genetically heterogeneous, and broad panel testing allows for an efficient evaluation of many potentially relevant genes based on a single clinical indication.

This test may be appropriate for individuals with a personal and/or family history of cancers across multiple organ systems. There are also common, general features suggestive of a hereditary cancer syndrome family. These include:
– cancer diagnosed at an unusually young age
– different types of cancer that have occurred independently in the same person
– cancer that has developed in both organs of a set of paired organs (e.g., both
kidneys; both breasts)
– several close blood relatives that have the same type of cancer
– unusual cases of a specific cancer type (e.g., breast cancer in a man)

Test Options
Multi cancer panel (84 genes)
Most Common Cancers panel (47 genes)
Breast and Gynecological Cancer Panel (28 genes)
Prostate Cancer Panel (16 genes)

To learn more about Invitae you can visit the link below:
https://www.invitae.com